Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Pacific Growth Maintains 'Overweight' on Transkaryotic

Transkaryotic Therapies (TKTX) entered into agreements with Genzyme (GENZ). Pacific Growth reiterated its overweight recommendation on Transkaryotic.

Analyst Thomas Dietz says Transkaryotic entered into various agreements with Genzyme, including granting Genzyme a license to develop and commercialize Transkaryotic's Hunters Syndrome product in the Pacific Rim, with Genzyme paying the company $1.5 million up front and 33% to 35% of sales. Dietz notes Transkaryotic also granted Genzyme an option to license its San Filipo product in the Pacific Rim. Further, Genzyme paid Transkaryotic $1.5 million to settle litigation between the two companies. The analyst says the Genzyme deals should reflect favorably on Transkaryotic's management team.

Dietz narrowed his 54-cent fourth quarter loss per share estimate for Transkaryotic to a loss of 50 cents, and his forecast of a $2.18 loss in 2003 to a $2.13 loss.

blog comments powered by Disqus